Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 28:13:100308.
doi: 10.1016/j.conctc.2018.100308. eCollection 2019 Mar.

The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol

N G M Oonk  1 , K L L Movig  2 , E M Munster  1 , K Koehorst-Ter Huurne  3   4 , J van der Palen  5   6 , L D A Dorresteijn  1
Affiliations

The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol

N G M Oonk et al. Contemp Clin Trials Commun. .

Abstract

Background: Treatment of Parkinson's disease (PD) is symptomatic and frequently consists of complicated medication regimes. This negatively influences therapy adherence, resulting in lower benefit of treatment, drug related problems and decreased quality of life (QoL). A potential effective intervention strategy is a structured medication review, executed by community pharmacists. However, little is known about the effects on clinical endpoints like QoL, as well as on feasibility and cost-effectiveness in PD patients.

Objectives: To assess the effect of a structured medication review on QoL in PD patients. Secondary objectives are measurements of physical disability, activities in daily life, non-motor symptoms, health state, personal carers' QoL and cost-effectiveness. Furthermore, a better insight in the process of performing medication reviews will be obtained from the perspective of community pharmacists.

Methods: In this multicenter randomized controlled trial we aim to enroll 200 PD patients from the outpatient clinic of three Dutch hospitals. Community pharmacists will perform a structured medication review in half of the assigned patients; the other half will receive usual care. Data obtained by use of six validated questionnaires will be collected at baseline and after 3 and 6 months of follow-up. Semi-structured interviews with community pharmacists will be conducted till data saturation has been reached.

Discussion: This trial targets a high-risk patient group for whom optimizing therapy by a structured medication review might be of added value. If effectiveness is proven, this could further promote the implementation of pharmaceutical care in a primary care setting.

Keywords: ALDS, Amsterdam Medical Center linear disability score; CDS, chronic disease score; DRP, drug related problem; EQ-5D-5L, EuroQOL-5 Dimensions-5 Levels; MID, minimally important difference; Medication; Medication review; NMS-Quest, non-motor symptoms questionnaire; PDQ, Parkinson's disease questionnaire; Parkinson's disease; Quality of life; SMR, structured medication review; Therapy adherence; VAS, Visual analogue scale.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design flowchart.
Image 1
Image 2
See this image and copyright information in PMC

References

    1. Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 2014;29(13):1583–1590. - PubMed
    1. Dorsey E., Constantinescu R., Thompson J., Biglan K., Holloway R., Kieburtz K. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. - PubMed
    1. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889–909. - PubMed
    1. Parkinson J. An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 2002;14(2):223–236. - PubMed
    1. Jankovic J. Parkinson's Disease: Diagnosis and Treatment. Dekker; New York: 1987. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease; pp. 99–126.